CITOKINE RELEASE SYNDROME MANAGEMENT IN ADULTS AND PEDIATRIC PATIENTS

Authors

  • Julia Lopes Garcia HIAE
  • Fabio Rodrigues Kerbauy BENEFICIENCIA Portuguesa / Unifesp

DOI:

https://doi.org/10.46765/2675-374X.2022v3n2p163

Keywords:

cytokine release syndrome. CRS. CAR T complications. Anti IL 6. Tocilizumab. Toxicity.

Abstract

Chimeric Antigen Receptor (CAR) T cell therapy has demonstrated efficacy in B cell malignances. However, the treatment is not harmless and, in some patients, can lead to a fatal endpoint. For this reason, the knowledge and the early recognition and management of the side effects related to CAR-T cell therapy for the multidisciplinary team is essential. In this article, we have summarized the current recommendations for identification, gradation and management of cytokine release syndrome related to CAR-T cell therapy.

Downloads

Published

11/23/2022

How to Cite

Garcia, J. L., & Rodrigues Kerbauy, F. . (2022). CITOKINE RELEASE SYNDROME MANAGEMENT IN ADULTS AND PEDIATRIC PATIENTS. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 3(2), 163. https://doi.org/10.46765/2675-374X.2022v3n2p163

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.